CN1679544A - 一种苯酞类二聚体的用途 - Google Patents
一种苯酞类二聚体的用途 Download PDFInfo
- Publication number
- CN1679544A CN1679544A CN 200410030989 CN200410030989A CN1679544A CN 1679544 A CN1679544 A CN 1679544A CN 200410030989 CN200410030989 CN 200410030989 CN 200410030989 A CN200410030989 A CN 200410030989A CN 1679544 A CN1679544 A CN 1679544A
- Authority
- CN
- China
- Prior art keywords
- cell
- adr
- drug
- tumor
- application according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 title description 6
- 239000003814 drug Substances 0.000 claims abstract description 44
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 230000000118 anti-neoplastic effect Effects 0.000 claims abstract description 12
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 33
- 229960004528 vincristine Drugs 0.000 claims description 32
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 31
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 23
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 23
- 229960000975 daunorubicin Drugs 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000036457 multidrug resistance Effects 0.000 claims description 14
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical group C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 10
- 229930195573 Amycin Natural products 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000000259 anti-tumor effect Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 18
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- UBBRXVRQZJSDAK-ZJHGLIIDSA-N (Z)-6,6',7,3'a-Diligustilide Chemical compound C([C@H](C=C1C(=O)OC/2=C\CCC)[C@@H]3CC4)C[C@]1\2[C@H]3C1=C4C(=C/CCC)/OC1=O UBBRXVRQZJSDAK-ZJHGLIIDSA-N 0.000 abstract 2
- UBBRXVRQZJSDAK-UHFFFAOYSA-N (Z)-6,6',7,3lpha-diligustilide Natural products C1CC2C(C=C3C(=O)OC4=CCCC)CCC34C2C2=C1C(=CCCC)OC2=O UBBRXVRQZJSDAK-UHFFFAOYSA-N 0.000 abstract 2
- BBKJNWQVMDPKPI-UHFFFAOYSA-N levistolide A Natural products CCCCC=C1/OC(=O)C2=C1CCC3C4CCC5(C23)C(=CCCC)OC(=O)C5=C4 BBKJNWQVMDPKPI-UHFFFAOYSA-N 0.000 abstract 2
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 59
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 42
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 206010059866 Drug resistance Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 5
- 241000233855 Orchidaceae Species 0.000 description 5
- 229940009456 adriamycin Drugs 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000008261 resistance mechanism Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960001722 verapamil Drugs 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000012313 reversal agent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000000205 computational method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000002456 taxol group Chemical group 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014842 Multidrug resistance proteins Human genes 0.000 description 1
- 108050005144 Multidrug resistance proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100400865 Mus musculus Abcb1b gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011208 chromatographic data Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108700025647 major vault Proteins 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
k562 | k562/adr | RF | kb | kbV200 | RF | |
ADRVCR | 0.215±0.1520.018±0.01 | 4.06±0.35>20 | 18.88>1120 | 0.4900.090 | 7.28>20 | 19.2>222 |
抗肿瘤药物 | |||
增敏剂 | ADR | VCR | DNR |
无VERLA | 2.288±0.2890.152±0.0210.189±0.015 | >>2019.48±0.35512.04±0.209 | 0.367±0.0160.075±0.0100.105±0.005 |
抗肿瘤药物 | |||
增敏剂 | ADR | VCR | DNR |
无VERLA | 1.970±0.1080.056±0.0190.040±0.013 | >209.171±0.5361.514±0.393 | 0.450±0.0630.028±0.004<0.01 |
RF(k562/adr) | RF(kbv200) | |||||
增敏剂 | ADR | VCR | DNR | ADR | VCR | DNR |
VERLA | 15.03212.122 | 1.0266>>1.661 | 4.89333.4952 | 35.17849.250 | 2.180713.210 | 16.07145.000 |
对照 | LA(5ug/ml) | LA(10ug/ml) | |
k562/adrkbv200 | 79.8%87.76% | 76.7%82.5% | 77.8%79.8% |
组别 | 瘤重(g) |
对照VCRVCR+LA1(6ug/ml)VCR+LA2(10ug/ml) | 0.95 8±0.3240.779±0.2670.631±0.174a0.519±0.246b |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100309897A CN1331469C (zh) | 2004-04-05 | 2004-04-05 | 一种苯酞类二聚体的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100309897A CN1331469C (zh) | 2004-04-05 | 2004-04-05 | 一种苯酞类二聚体的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679544A true CN1679544A (zh) | 2005-10-12 |
CN1331469C CN1331469C (zh) | 2007-08-15 |
Family
ID=35066567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100309897A Expired - Lifetime CN1331469C (zh) | 2004-04-05 | 2004-04-05 | 一种苯酞类二聚体的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1331469C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007036074A1 (fr) * | 2005-09-30 | 2007-04-05 | Fei Chen | Utilisation de dérivés du phthalide |
WO2008089594A1 (fr) * | 2007-01-19 | 2008-07-31 | Fei Chen | Utilisation de dipolymères de phtalide comme agent antitumoral |
CN102772400A (zh) * | 2012-01-12 | 2012-11-14 | 上海中医药大学 | 欧当归内酯a的医药用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996016053A1 (en) * | 1994-11-21 | 1996-05-30 | Pfizer Pharmaceuticals Inc. | Phthalide compounds and their production process |
JPH1059938A (ja) * | 1996-06-12 | 1998-03-03 | Ishihara Sangyo Kaisha Ltd | N−フェニルイミド系化合物又はその塩、それらの製造方法及びそれらを含有する医薬組成物 |
CN1086942C (zh) * | 1998-12-18 | 2002-07-03 | 中国医学科学院药物研究所 | 丁基苯酞在制备抗血栓形成及抗血小板聚集药物中的应用 |
CN1375288A (zh) * | 2002-05-13 | 2002-10-23 | 周桂荣 | 一种治疗脑血管疾病的药物组合物 |
-
2004
- 2004-04-05 CN CNB2004100309897A patent/CN1331469C/zh not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007036074A1 (fr) * | 2005-09-30 | 2007-04-05 | Fei Chen | Utilisation de dérivés du phthalide |
JP2009511436A (ja) * | 2005-09-30 | 2009-03-19 | チェン、フェイ | フタリド誘導体の使用 |
US8445532B2 (en) | 2005-09-30 | 2013-05-21 | Fei Chen | Use of phthalide derivatives |
WO2008089594A1 (fr) * | 2007-01-19 | 2008-07-31 | Fei Chen | Utilisation de dipolymères de phtalide comme agent antitumoral |
JP2010516632A (ja) * | 2007-01-19 | 2010-05-20 | チェン、フェイ | フタリド化合物のダイマーの抗腫瘍作用 |
US8247444B2 (en) | 2007-01-19 | 2012-08-21 | Fei Chen | Anti-tumor effect of dimeric phthalide compound |
CN102772400A (zh) * | 2012-01-12 | 2012-11-14 | 上海中医药大学 | 欧当归内酯a的医药用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1331469C (zh) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101321528B (zh) | 治疗增殖性疾病或炎症的3,11b-顺式-二氢丁苯那嗪 | |
US20200069677A1 (en) | Markers for personalized cancer treatment with lsd1 inhibitors | |
TW200819456A (en) | Cancer therapy with cantharidin and cantharidin analogs | |
CN105246887A (zh) | 香豆素衍生物以及用于治疗过度增生性疾病的方法 | |
CN1712399A (zh) | 紫杉醇和免疫增强剂胞壁酰二肽共轭物的制备及用途 | |
CN104371009B (zh) | GnRH多肽‑甲氨蝶呤偶联物、其制备方法及用途 | |
US20200289520A1 (en) | Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma | |
CN101058578A (zh) | 右旋去氧娃儿藤宁、其制法和其药物组合物与用途 | |
CN1095844C (zh) | 雷公藤内酯醇衍生物,制备方法及其应用 | |
CN1679544A (zh) | 一种苯酞类二聚体的用途 | |
CN1281210C (zh) | 五味子乙素在制备治疗肿瘤药物中的应用 | |
CN1620305A (zh) | 诱导凋亡的方法和诱导凋亡的组合物 | |
CN1425667A (zh) | 一种具有抗肿瘤作用的新化合物、其制备方法及在制备治疗肿瘤药物中的应用 | |
CN114805117B (zh) | 抗肿瘤干细胞的紫草素及阿卡宁肟衍生物 | |
CN1445242A (zh) | 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物 | |
CN1339970A (zh) | 抗癌药物增强剂 | |
CN1583803A (zh) | 具有增强免疫和抗肿瘤活性的厚壳贻贝多糖mf4 | |
CN1102047C (zh) | 一种新的肿瘤细胞多药耐药性逆转剂 | |
CN1418633A (zh) | 一种以20(s)-原人参二醇为有效成分的抗癌辅助药物及应用 | |
CN108472296A (zh) | Akt2在诊断和治疗肿瘤中的用途 | |
CN1806794A (zh) | 抗急性髓性白血病的gm-csf靶向药物脂质体及制备方法 | |
CN1580043A (zh) | 抗恶性肿瘤南柴胡萃取物的制备方法 | |
CN1443777A (zh) | 一种能识别肿瘤细胞表面抗原的单克隆抗体及制备和应用 | |
CN1283236C (zh) | 和厚朴酚在制备抗肿瘤多药耐药性药物中的用途 | |
CN1259048C (zh) | 联苯双酯作为肿瘤多药耐药逆转剂的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SUZHOU MICRODIAG BIOMEDICINE Co.,Ltd. Assignor: Chen Fei|Wang Tao Contract record no.: 2010320000866 Denomination of invention: Use of dipolymer of phthalide Granted publication date: 20070815 License type: Exclusive License Open date: 20051012 Record date: 20100706 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151123 Address after: 215123, 99 Jinji Avenue, Suzhou Industrial Park, Jiangsu, Suzhou, 16 North West District Patentee after: PUSHI HUAKANG JIANGSU MEDICAL TECHNOLOGY Co.,Ltd. Address before: 310027, Zhejiang, Hangzhou, Xinhua Road, Temple of water and land Lane 3-3-601 Patentee before: Wang Tao Patentee before: Chen Fei |
|
TR01 | Transfer of patent right |
Effective date of registration: 20211125 Address after: 215127 rooms 201 and 301, C4 building, biological nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou, Jiangsu Province Patentee after: JIANGSU MICRODIAG BIOMEDICINE TECHNOLOGY Co.,Ltd. Address before: 215123 building 16, Northwest District, Suzhou nano City, No. 99, Jinji Avenue, Suzhou Industrial Park, Jiangsu Province Patentee before: PUSHI HUAKANG JIANGSU MEDICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070815 |